305 related articles for article (PubMed ID: 27908305)
1. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.
Haacke EA; van der Vegt B; Meiners PM; Vissink A; Spijkervet FK; Bootsma H; Kroese FG
Clin Exp Rheumatol; 2017; 35(2):317-320. PubMed ID: 27908305
[TBL] [Abstract][Full Text] [Related]
2. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome.
Verstappen GM; Meiners PM; Corneth OBJ; Visser A; Arends S; Abdulahad WH; Hendriks RW; Vissink A; Kroese FGM; Bootsma H
Arthritis Rheumatol; 2017 Sep; 69(9):1850-1861. PubMed ID: 28564491
[TBL] [Abstract][Full Text] [Related]
4. FcRL4
Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
[TBL] [Abstract][Full Text] [Related]
5. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
6. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
7. CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren's syndrome.
Jin L; Yu D; Li X; Yu N; Li X; Wang Y; Wang Y
Int J Clin Exp Pathol; 2014; 7(5):1988-96. PubMed ID: 24966908
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.
Pijpe J; Meijer JM; Bootsma H; van der Wal JE; Spijkervet FK; Kallenberg CG; Vissink A; Ihrler S
Arthritis Rheum; 2009 Nov; 60(11):3251-6. PubMed ID: 19877054
[TBL] [Abstract][Full Text] [Related]
9. Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren's syndrome are not predictive for parotid MALT lymphoma development.
Haacke EA; van der Vegt B; Vissink A; Spijkervet FKL; Bootsma H; Kroese FGM
Ann Rheum Dis; 2017 Oct; 76(10):1781-1784. PubMed ID: 28710097
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study.
Adler S; Körner M; Förger F; Huscher D; Caversaccio MD; Villiger PM
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1862-8. PubMed ID: 23740889
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of germinal center-like structures in patients with Sjögren's syndrome.
He J; Jin Y; Zhang X; Zhou Y; Li R; Dai Y; Sun X; Zhao J; Guo J; Li Z
Int J Rheum Dis; 2017 Feb; 20(2):245-251. PubMed ID: 28556615
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome.
Gong YZ; Nititham J; Taylor K; Miceli-Richard C; Sordet C; Wachsmann D; Bahram S; Georgel P; Criswell LA; Sibilia J; Mariette X; Alsaleh G; Gottenberg JE
J Autoimmun; 2014 Jun; 51():57-66. PubMed ID: 24411167
[TBL] [Abstract][Full Text] [Related]
14. Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sjögren's syndrome patients.
van Ginkel MS; Haacke EA; Bootsma H; Arends S; van Nimwegen JF; Verstappen GM; Spijkervet FKL; Vissink A; van der Vegt B; Kroese FGM
Clin Exp Rheumatol; 2019; 37 Suppl 118(3):42-48. PubMed ID: 31074726
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
[TBL] [Abstract][Full Text] [Related]
16. Diffusion-weighted magnetic resonance imaging of parotid glands before and after abatacept therapy in patients with Sjögren's syndrome associated with rheumatoid arthritis: Utility to evaluate and predict response to treatment.
Takahashi H; Tsuboi H; Yokosawa M; Asashima H; Hirota T; Kondo Y; Matsumoto I; Sumida T
Mod Rheumatol; 2018 Mar; 28(2):300-307. PubMed ID: 28722506
[TBL] [Abstract][Full Text] [Related]
17. Invariant NKT cells are expanded in peripheral blood but are undetectable in salivary glands of patients with primary Sjögren's syndrome.
Guggino G; Ciccia F; Raimondo S; Giardina G; Alessandro R; Dieli F; Sireci G; Triolo G
Clin Exp Rheumatol; 2016; 34(1):25-31. PubMed ID: 26633038
[TBL] [Abstract][Full Text] [Related]
18. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
19. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.
Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM
Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
